Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 11 studies | 34% ± 16% | |
endothelial cell | 7 studies | 21% ± 5% | |
type I pneumocyte | 6 studies | 26% ± 4% | |
retinal cone cell | 6 studies | 32% ± 11% | |
dendritic cell | 5 studies | 21% ± 6% | |
classical monocyte | 5 studies | 18% ± 2% | |
epithelial cell | 5 studies | 33% ± 18% | |
macrophage | 5 studies | 17% ± 1% | |
mast cell | 4 studies | 21% ± 3% | |
pericyte | 4 studies | 21% ± 5% | |
oligodendrocyte | 4 studies | 20% ± 4% | |
non-classical monocyte | 3 studies | 19% ± 2% | |
conventional dendritic cell | 3 studies | 19% ± 3% | |
myeloid cell | 3 studies | 22% ± 0% | |
retinal rod cell | 3 studies | 20% ± 5% | |
fibroblast | 3 studies | 18% ± 3% | |
oligodendrocyte precursor cell | 3 studies | 27% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2846.20 | 1445 / 1445 | 100% | 40.88 | 183 / 183 |
brain | 100% | 4975.08 | 2641 / 2642 | 100% | 62.68 | 705 / 705 |
lung | 100% | 4331.24 | 578 / 578 | 100% | 33.95 | 1152 / 1155 |
ovary | 100% | 2648.53 | 180 / 180 | 99% | 30.76 | 427 / 430 |
thymus | 100% | 4301.37 | 653 / 653 | 99% | 54.21 | 600 / 605 |
stomach | 100% | 2269.07 | 359 / 359 | 99% | 27.00 | 283 / 286 |
intestine | 100% | 2264.96 | 966 / 966 | 99% | 23.71 | 521 / 527 |
uterus | 100% | 2724.15 | 170 / 170 | 98% | 32.21 | 451 / 459 |
prostate | 100% | 2071.04 | 245 / 245 | 98% | 24.16 | 492 / 502 |
breast | 100% | 2369.84 | 459 / 459 | 98% | 41.79 | 1093 / 1118 |
bladder | 100% | 2458.33 | 21 / 21 | 97% | 24.90 | 491 / 504 |
skin | 100% | 2775.15 | 1808 / 1809 | 97% | 35.40 | 459 / 472 |
kidney | 100% | 1993.57 | 89 / 89 | 94% | 21.77 | 851 / 901 |
pancreas | 95% | 1262.44 | 313 / 328 | 99% | 28.43 | 176 / 178 |
liver | 96% | 1603.40 | 216 / 226 | 95% | 29.75 | 386 / 406 |
adrenal gland | 100% | 1810.71 | 258 / 258 | 78% | 11.30 | 180 / 230 |
adipose | 100% | 2675.23 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4498.85 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 2038.32 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.29 | 1 / 1 |
muscle | 100% | 1729.69 | 799 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 29.24 | 44 / 45 |
heart | 93% | 1591.50 | 805 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 18.19 | 72 / 80 |
lymph node | 0% | 0 | 0 / 0 | 86% | 19.46 | 25 / 29 |
peripheral blood | 75% | 898.28 | 697 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007165 | Biological process | signal transduction |
GO_0045786 | Biological process | negative regulation of cell cycle |
GO_0072332 | Biological process | intrinsic apoptotic signaling pathway by p53 class mediator |
GO_1900119 | Biological process | positive regulation of execution phase of apoptosis |
GO_0030054 | Cellular component | cell junction |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0051059 | Molecular function | NF-kappaB binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0002039 | Molecular function | p53 binding |
GO_0017124 | Molecular function | SH3 domain binding |
Gene name | TP53BP2 |
Protein name | Apoptosis-stimulating of p53 protein 2 (Bcl2-binding protein) (Bbp) (Renal carcinoma antigen NY-REN-51) (Tumor suppressor p53-binding protein 2) (53BP2) (p53-binding protein 2) (p53BP2) TP53BP2 protein Tumor protein p53 binding protein 2 |
Synonyms | ASPP2 BBP |
Description | FUNCTION: Regulator that plays a central role in regulation of apoptosis and cell growth via its interactions with proteins such as TP53 . Regulates TP53 by enhancing the DNA binding and transactivation function of TP53 on the promoters of proapoptotic genes in vivo. Inhibits the ability of NAE1 to conjugate NEDD8 to CUL1, and thereby decreases NAE1 ability to induce apoptosis. Impedes cell cycle progression at G2/M. Its apoptosis-stimulating activity is inhibited by its interaction with DDX42. . |
Accessions | H0Y847 ENST00000483398.5 ENST00000391878.6 [Q13625-2] Q13625 H7C5L8 Q05BL1 ENST00000343537.12 [Q13625-3] ENST00000494100.1 |